ArticleToxins2018
Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of
Article in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04996264 (Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes
Who cites it
39 citing papers in PubMed.
- Adjunctive Varespladib after antivenom administration for snakebite: A phase II randomized clinical trial.PLoS neglected tropical diseases · 2026Trial
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
- Article
- Preclinical evidence of adenosine for early intervention in Bungarus multicinctus envenomation.Journal of advanced research · 2026Article
- Large animal models for the assessment of snakebite envenoming therapies.npj drug discovery · 2026Review
- Preclinical evaluation of small molecule inhibitors as early intervention therapeutics against Russell's viper envenoming in India.Communications medicine · 2025Article
- Article
- Article
- Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms.Nature communications · 2023Article
- Considerations for the development of a field-based medical device for the administration of adjunctive therapies for snakebite envenoming.Toxicon: X · 2023Article
- Unraveling snake venom phospholipase APharmacological reports : PR · 2023Review
- Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and PapuanToxins · 2023Article
- Cardiac Effects of Micrurus corallinus and Micrurus dumerilii carinicauda (Elapidae) Venoms and Neutralization by Brazilian Coralsnake Antivenom and Varespladib.Cardiovascular toxicology · 2023Article
- Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform.Frontiers in pharmacology · 2023Article
- Article
- Inhibitory Effects of Varespladib, CP471474, and Their Potential Synergistic Activity onMolecules (Basel, Switzerland) · 2022Article
- Review
- Article
- Article
- Rattlesnake envenomation in 2 Visayan warty pigs.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is a clear, unmet need for effective, lightweight, shelf-stable and economical snakebite envenoming therapies that can be given rapidly after the time of a snake's bite and as adjuncts to antivenom therapies in the hospital setting. The sPLA2 inhibitor, LY315920, and its orally bioavailable prodrug, LY333013, demonstrate surprising efficacy and have the characteristics of an antidote with potential for both field and hospital use.
methodsThe efficacy of the active pharmaceutical ingredient (LY315920) and its prodrug (LY333013) to treat experimental, lethal envenoming by
results14 of 14 animals (100%) receiving either LY315920 (intravenous) and/or LY333013 (oral) survived to the 120 h endpoint despite, in some protocols, the presence of severe neurotoxic signs. The study drugs demonstrated the ability to treat, rescue, and re-rescue animals with advanced manifestations of envenoming.
conclusionsLow molecular mass sPLA2 inhibitors were highly effective in preventing lethality following experimental envenoming by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.